Heteroaryl Estrogen Receptor Modulators for Resistant Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new estrogen receptor-alpha (ER-α) targeting agents that are effective in treating metastatic disease and acquired resistance, particularly in breast cancer, where existing therapies are insufficient due to ligand-independent activity conferred by ESR1 mutations.
Innovation Solution
Development of heteroaryl compounds with specific structures (Formulas I, II, and III) that modulate estrogen receptor activity, potentially acting as selective estrogen receptor degraders (SERDs) to reduce steady-state ER-α levels, thereby treating ER-α positive breast cancer and other estrogen-sensitive conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing estrogen receptor therapies are used, then treatment of early-stage breast cancer is effective, but they fail to treat metastatic disease and acquired resistance due to ligand-independent activity from ESR1 mutations
Solution Approach 1:
The patent modifies the chemical structure of estrogen receptor modulators by introducing specific heteroaryl groups at the R1 position (pyridine, pyrimidine, triazine rings) and adjusting substituents to create compounds that bind to mutant ER-α variants. This structural parameter change enables the compounds to maintain binding affinity despite conformational changes in mutated receptors, thereby treating acquired resistance while preserving efficacy in metastatic disease.
2Reliability
If new heteroaryl compounds are developed to target mutant ER-α, then efficacy in resistant disease improves, but complexity of compound structure increases
Solution Approach 1:
The patent divides the estrogen receptor modulator into distinct functional segments: a core steroid-like structure for receptor binding, heteroaryl groups at the R1 position for selective interaction with mutant ER-α variants, and specific substituents for optimizing pharmacokinetic properties. This segmentation allows each part to fulfill a specific function, improving efficacy against resistant disease while managing overall molecular complexity through modular design.
Solution Approach 2:
The heteroaryl compounds described in the patent are designed to perform multiple functions: they bind to both wild-type and mutant ER-α receptors, act as selective estrogen receptor degraders (SERDs), and exhibit improved pharmacokinetic properties. This multi-functionality is achieved through the versatile heteroaryl structure that can interact with various ER-α variants while maintaining a relatively streamlined core architecture, balancing complexity with therapeutic versatility.
Data Source
AI summary
Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures:andstereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.